Burlingame, California-based Enliven Therapeutics, Inc. (Nasdaq: ELVN) announced the pricing of an upsized underwritten public offering of common stock and pre-funded warrants, raising approximately USD 400 million in gross proceeds to fund continued clinical development of its small molecule oncology pipeline. The offering was upsized from an initial target of USD 250 million, a roughly 60% increase that indicates strong institutional demand for the clinical-stage biopharmaceutical stock offering.
In terms of the offering specifics, 8,933,334 shares of common stock priced at USD 37.50 per share were issued, with certain investors electing to receive pre-funded warrants to purchase up to 1,733,333 shares at USD 37.499 per warrant. Underwriters were granted a 30-day option to purchase up to an additional 1,600,000 shares, which is not reflected in the USD 400 million gross proceeds figure. The transaction was expected to close on or about June 15, 2026, subject to customary closing conditions. This pre-funded warrants offering follows a USD 230 million public offering closed in June 2025 — which itself included full exercise of the underwriters' overallotment option — and a USD 90 million PIPE financing in March 2024, reflecting a consistent escalation in deal size as the pipeline has advanced.
Company overview and pipeline
The California-based Enliven is focused on small-molecule kinase inhibitors for cancer. The lead asset, ELVN-001, is a BCR-ABL1 inhibitor in development for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is designed to overcome resistance mutations, including the T315I gatekeeper mutation, that limit the efficacy of approved tyrosine kinase inhibitors such as imatinib, dasatinib, and ponatinib. Enliven has positioned ELVN-001 as differentiated by its potency and selectivity profile relative to existing agents. The company's second clinical asset, ELVN-002, is a HER2-selective inhibitor being developed for HER2-mutant solid tumors, a space where approved agents include tucatinib and neratinib, with additional investigational assets in development at multiple companies.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article